Russian pharmaceutical companies plan to significantly increase the volume of investments in the conduct of clinical trials of their drugs over the next few years, according to recent statements of drugmakers.
To date, certain companies have already increased the volume of investments for clinical trials, reports The Pharma Letter’s local correspondent.
For example, Biocad, one of Russia’s leading drugmakers, last year increased the volume of investments in conducting clinical trials by more than five-fold - up to 1 billion roubles ($15.6 million), compared to previous years, considering further increase this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze